Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
Alkermes (ALKS) reported $380.94 million in revenue for the quarter ended September 2023, representing a year-over-year increase of 51%. EPS of $0.64 for the same period compares to $0.02 a year ago.
The reported revenue represents a surprise of +4.03% over the Zacks Consensus Estimate of $366.18 million. With the consensus EPS estimate being $0.44, the EPS surprise was +45.45%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Alkermes performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- Manufacturing and Royalty revenues: $149.11 million versus the six-analyst average estimate of $124.99 million. The reported number represents a year-over-year change of +181.7%.
Revenues- Product sales, net: $231.82 million versus $243.17 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +16.3% change.
Revenues- Key Commercial Product Revenues- LYBALVI: $50.70 million versus $53.97 million estimated by three analysts on average.
Revenues- Key Commercial Product Revenues- VUMERITY: $34.60 million versus $33.22 million estimated by three analysts on average.
Revenues- Key Commercial Product Revenues- ARISTADA: $81.80 million versus the three-analyst average estimate of $85.14 million. The reported number represents a year-over-year change of +8.1%.
Revenues- Key Commercial Product Revenues- VIVITROL: $99.30 million versus $104.08 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +2.9% change.
Revenues- Research and development revenue: $0 million compared to the $0.03 million average estimate based on two analysts. The reported number represents a change of -91.7% year over year.
View all Key Company Metrics for Alkermes here>>>
Shares of Alkermes have returned -12.6% over the past month versus the Zacks S&P 500 composite's -1.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS) : Free Stock Analysis Report
